- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenetics of chemotherapy efficacy in breast cancer
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 13, Issue 6, Pages 677-690
Publisher
Future Medicine Ltd
Online
2012-04-19
DOI
10.2217/pgs.12.44
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
- (2011) C. Tibaldi et al. ANNALS OF ONCOLOGY
- From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource
- (2011) Ellen M McDonagh et al. Biomarkers in Medicine
- Breast cancer statistics, 2011
- (2011) Carol DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer
- (2011) M. J. Deenen et al. CLINICAL CANCER RESEARCH
- ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis
- (2011) Ming Yin et al. CLINICAL CANCER RESEARCH
- Association of RRM1 –37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy
- (2011) J. Rodriguez et al. EUROPEAN JOURNAL OF CANCER
- Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
- (2011) L. B. Ramsey et al. GENOME RESEARCH
- A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese
- (2011) Kazuma Kiyotani et al. HUMAN MOLECULAR GENETICS
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast Cancer
- (2011) Colin F. Spraggs et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-wide association study of epirubicin-induced leukopenia in Japanese patients
- (2011) Yuvaraj Srinivasan et al. Pharmacogenetics and Genomics
- TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients
- (2011) A. Fariña-Sarasqueta et al. CELLULAR ONCOLOGY
- Association of CYP1B1 with hypersensitivity induced by Taxane therapy in breast cancer patients
- (2010) Roberta Rizzo et al. BREAST CANCER RESEARCH AND TREATMENT
- Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
- (2010) J Bray et al. BRITISH JOURNAL OF CANCER
- Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast Cancer
- (2010) S. Yao et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism
- (2010) Jan Gerard Maring et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients
- (2010) Songjian Chen et al. INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH
- Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil
- (2010) David Páez et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Impact of Cytidine Deaminase Polymorphisms on Toxicity After Gemcitabine: The Question Is Still Ongoing
- (2010) Elisa Giovannetti et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of DNA Repair Gene Polymorphisms With Response to Platinum-Based Doublet Chemotherapy in Patients With Non–Small-Cell Lung Cancer
- (2010) Kouya Shiraishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors
- (2010) James N. Ingle et al. JOURNAL OF CLINICAL ONCOLOGY
- RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy
- (2010) Song Dong et al. Journal of Hematology & Oncology
- Population-based differences in treatment outcome following anticancer drug therapies
- (2010) Brigette BY Ma et al. LANCET ONCOLOGY
- No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: A meta-analysis
- (2010) Ming Yin et al. LUNG CANCER
- Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis
- (2010) Shu-zhen Wei et al. MEDICAL ONCOLOGY
- International network of cancer genome projects
- (2010) Thomas J. Hudson (Chairperson) et al. NATURE
- Genome-wide association studies in pharmacogenomics
- (2010) Ann K. Daly NATURE REVIEWS GENETICS
- Uncovering the roles of rare variants in common disease through whole-genome sequencing
- (2010) Elizabeth T. Cirulli et al. NATURE REVIEWS GENETICS
- Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity
- (2010) Lu Fan et al. Pharmacogenetics and Genomics
- Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response
- (2010) Kazuma Kiyotani et al. Pharmacogenetics and Genomics
- The past, present and future of pharmacoepigenomics
- (2010) Magnus Ingelman-Sundberg et al. PHARMACOGENOMICS
- High-Resolution Melting Analysis of Sequence Variations in the Cytidine Deaminase Gene (CDA) in Patients With Cancer Treated With Gemcitabine
- (2010) Caroline Raynal et al. THERAPEUTIC DRUG MONITORING
- Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
- (2009) W Chua et al. BRITISH JOURNAL OF CANCER
- Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients
- (2009) H Ueno et al. BRITISH JOURNAL OF CANCER
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity
- (2009) T. Okazaki et al. CLINICAL CANCER RESEARCH
- Targeted Chemotherapy? Platinum in BRCA1-Dysfunctional Breast Cancer
- (2009) Lisa A. Carey JOURNAL OF CLINICAL ONCOLOGY
- Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
- (2009) Tomasz Byrski et al. JOURNAL OF CLINICAL ONCOLOGY
- Taxane pathway
- (2009) Connie Oshiro et al. Pharmacogenetics and Genomics
- Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients
- (2008) H. Chang et al. ANNALS OF ONCOLOGY
- Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
- (2008) T. Byrski et al. BREAST CANCER RESEARCH AND TREATMENT
- Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients
- (2008) Suman Lal et al. CANCER SCIENCE
- Pharmacogenetic Pathway Analysis of Docetaxel Elimination
- (2008) SD Baker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression
- (2008) N. Ribelles et al. CURRENT DRUG METABOLISM
- Clinical Pharmacogenetics and Potential Application in Personalized Medicine
- (2008) Shu-Feng Zhou et al. CURRENT DRUG METABOLISM
- Anthracycline Cardiotoxicity: From Bench to Bedside
- (2008) Luca Gianni et al. JOURNAL OF CLINICAL ONCOLOGY
- Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel
- (2008) T. M. Sissung et al. MOLECULAR CANCER THERAPEUTICS
- Prediction of paclitaxel resistance in breast cancer: isCYP1B1*3a new factor of influence?
- (2008) Mathias Gehrmann et al. PHARMACOGENOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started